Low-Dose Klonopin Gets FDA Generic Approval Nod
Published Date: 2/23/2026
Notice
Summary
The FDA has decided that Klonopin tablets in 0.125 mg and 0.25 mg strengths were not taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their versions of these Klonopin tablets, as long as they meet all other rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Klonopin Applications Allowed
The FDA determined on February 23, 2026, that KLONOPIN (clonazepam) tablets, 0.125 mg and 0.25 mg, were not withdrawn from sale for reasons of safety or effectiveness. That determination allows generic drug makers to submit abbreviated new drug applications (ANDAs) for those two strengths and for FDA to approve such ANDAs if they meet all other legal and regulatory requirements, which could lead to more affordable options for patients and pharmacies.
FDA Confirms No Safety Withdrawal
After reviewing a citizen petition (dated June 20, 2025) and Agency records, the FDA found no data showing that KLONOPIN (clonazepam) tablets, 0.125 mg and 0.25 mg, were withdrawn from sale for reasons of safety or effectiveness. The Agency also reviewed relevant literature and postmarketing adverse event information and will continue to list these strengths in the Orange Book's Discontinued Drug Product List as discontinued for reasons other than safety or effectiveness.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12167 — Andrew Jonathan Morgan: Final Debarment Order
Andrew Jonathan Morgan is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on June 17, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping things safe and legal.
2026-12165 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
Previous / Next Documents
Previous: 2026-03493 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; WASKYRA (etuvetidigene autotemcel)
The FDA just gave a special fast-track prize called a Priority Review Voucher to Fondazione Telethon ETS for their rare disease treatment, WASKYRA, approved in December 2025. This medicine helps kids and adults with Wiskott-Aldrich Syndrome who need a stem cell transplant but can’t find a perfect donor. This voucher speeds up future drug reviews and can be sold, saving time and money for drug developers.
Next: 2026-03496 — Rural Opportunities To Use Transportation for Economic Success Initiative: Request for Information
The Department of Transportation wants to hear from rural and Tribal communities about their transportation needs and challenges. They’re working on making it easier to find funding and get help to improve roads, bridges, and transit in these areas. You’ve got 60 days to share your thoughts and help shape better support for rural America’s transportation future!